Application of co-grinding to formulate a model pMDI suspension

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 48, Issue 2, 1999, Pages 131-140

  Williams III, Robert O ^a   Repka, Michael A ^a   Barron, Melisa K ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Co grinding; Co polymer; Pluronic F77 ; Pressurized metered dose inhaler; Surfactant; Suspension

Indexed keywords

APAFLURANE; NORFLURANE; P134A; P227; POLOXAMER; SURFACTANT; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MANUFACTURE; DRUG MIXTURE; DRUG SOLUBILITY; INFRARED SPECTROPHOTOMETRY; LIGHT SCATTERING; PARTICLE SIZE; SUSPENSION; VISCOSITY;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POLOXAMER; RHEOLOGY; SOLUBILITY; SURFACE-ACTIVE AGENTS; SUSPENSIONS; TRIAMCINOLONE ACETONIDE; VOLATILIZATION;

EID: 0032814831     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(99)00027-2     Document Type: Article

References (32)

1. Kempner N. Metered dose inhaler CFCs under pressure. Pharm. J. 9:1990;428-429.
2. Dalby R.N., Byron P.R., Sheperd H.R., Papadopoulos E. Propellant substitution: P-134a as a potential replacement for P-12 in MDIs. Pharm. Technol. 3:1990;26-33.
3. Williams R.O. III, Repka M., Liu J. Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler. Drug Dev. Ind. Pharm. 24:1998;763-770.
4. M.-Y.F. Lu, A.L. Adjei, P.K. Gupta, Aerosol Drug Formulations Containing Polycgycolyzed Glycerides, US Patent 5,635,159 (1997).
5. P. Byron, F. Blondino, Pharmaceutically Acceptable Agents for Solubilizing, Wetting, Emulsifying or Lubricating in Metered Dose Inhaler Formulations Which Use HFC-227 Propellant, US Patent 5,508,023 (1996).
6. Wade A., Weller P.J. Handbook of Pharmaceutical Excipients. 2nd ed. 1994;The Pharmaceutical Press, London. pp. 327-334.
7. Martini A., Torricelli C., De Ponti R. Physico-pharmaceutical characteristics of steroid/crosslinked polyvinylpyrrolidone co ground systems. Int. J. Pharm. 75:1991;141-146.
8. Otsuka M., Matsuda Y. Effect of co grinding with various kinds of surfactants on the dissolution behavior of phenytoin. J. Pharm. Sci. 84:1995;1434-1437.
9. BASF Performance Chemicals: Pluronic & Tetronic Surfactants, BASF Corporation, Mount Olive, NJ, 1996, pp. 1-25.
10. US Pharmacopoeia XXII, United States Pharmacopeial Convention, Rockville, MD, 1990, pp. 3011-3014.
11. Miller N.C., Schultz R.K. Inter-particle interaction in non-polar liquid media and its influence on dose reproducibility. J. Biopharm. Sci. 3:1992;19-25.
12. Martin A.P. Physical Pharmacy. 4th ed. 1993;Lea & Febiger, Philadelphia. pp. 566-568.
13. Lefebvre A.H. Atomization and Sprays. 1989;Hemisphere Publication Corporation, New York. pp. 123-130.
14. Dalby R.N., Phillips E.M., Byron P.R. Determination of drug solubility in aerosol propellants. Pharm. Res. 8:1991;1206-1209.
15. Williams R.O. III, Brown J., Liu J. Influence of micronization technique on a pMDI formulation using HFA 134a as propellant. Pharm. Dev. Technol. 1999;. in press.
16. Williams R.O. III, Liu J. Influence of formulation additives on the vapor pressure of hydrofluoroalkane propellants. Int. J. Pharm. 166:1998;101-105.
17. Fresenius W., Huber J.F.K., Pungor E., Rechnitz G.A., Simon W., West Th.S. Tables of Spectral Data for Structure Determination of Organic Compounds. 2nd ed. 1989;Springer-Verlag, Berlin. pp. 54-57.
18. Eriksson P.M., Sandström K.B., Rosenholm J.B. The distribution of oleic acid between salbutamol base drug and different propellant blends. Pharm. Res. 12:1995;715-719.
19. Ford J.L., Timmins P. Horwood C.E. Pharmaceutical Thermal Analysis. 1989;96 Halsted Press, New York.
20. Heyder J., Gebhart J., Rudolf G., Schiller C.F., Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 mm. J. Aerosol Sci. 17:1986;811-825.
21. Finlay W.H., Stapleton K.W., Zuberbuhler P. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols. J. Aerosol Sci. 28:1997;1301-1309.
22. Parsons G.E., Buckton G., Chatham S.M. The use of surface energy and polarity determinations to predict physical stability of non-polar, non-aqueous suspensions. Int. J. Pharm. 83:1992;163-170.
23. Ranucci J.A., Dixit S., Bray R.N. Jr., Goldman D. Controlled flocculation in metered-dose aerosol suspensions. Pharm. Tech. 4:1990;68-74.
24. Clarke J.G., Wicks S.R., Farr S.J. Surfactant mediated effects urized metered dose inhalers formulated as suspensions. I. Drug/surfactant interactions in a model propellant system. Int. J. Pharm. 93:1993;221-231. in press.
25. Levine I.N. Physical Chemistry. 4th ed. 1995;McGraw-Hill, New York. pp. 225-226.
26. Mura P., Manderioli A., Bramanti G., Furlanetto S., Pinzauti S. Utilization of differential scanning calorimetry as a screening technique to determine the compatability of ketoprofen with excipients. Int. J. Pharm. 119:1995;71-79.
27. H. Nguyen, G. Rowley, O. Cassidy, S. Fuller, Adsorption of Poloxamers on Two Hydrophobic Drugs, The 17th Pharmaceutical Technology Conference and Exhibition (Trinity College, Dublin), Vol. 2, 1998.
28. Lieberman H.A., Rieger M.M., Banker G.S. Pharmaceutical Dosage Forms: Disperse Systems. 1:1996;Marcel Dekker, New York. pp. 287-313.
29. Bower C., Washington C., Purewal T.S. The effect of surfactant and solid phase concentration on drug aggregates in model aerosol propellant suspensions. J. Pharm. Pharmacol. 48:1996;342-346.
30. Sidhu B.K., Washington C., Davis S.S., Purewal T.S. Rheology of model aerosol suspensions. J. Pharm. Pharmacol. 45:1993;597-600.
31. Hickey A.J., Dalby R.N., Byron P.R. Effects of surfactants on aerosol powders in suspension. implications for airborne particle size. Int. J. Pharm. 42:1988;267-270.
32. Sandstrom K.B., Eriksson P.M., Rosenholm J.B. Electrophoretic mobility of salbutamol drug powder in mixed propellant solvents. J. Pharm. Sci. 83:1994;1380-1385.